Morgan Stanley Has Lowered Expectations for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN) had its price objective reduced by Morgan Stanley from $49.00 to $45.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued reports about the stock. The Goldman Sachs Group dropped their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. BMO Capital Markets dropped their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Silence Therapeutics Price Performance

Shares of SLN opened at $4.73 on Wednesday. The firm has a market capitalization of $141.57 million, a PE ratio of -3.01 and a beta of 1.05. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72. The company’s fifty day moving average price is $5.49 and its 200-day moving average price is $11.53.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Woodline Partners LP raised its position in shares of Silence Therapeutics by 22.6% in the fourth quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock worth $3,431,000 after acquiring an additional 91,829 shares during the period. Two Sigma Advisers LP raised its position in shares of Silence Therapeutics by 18.6% in the fourth quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock worth $680,000 after acquiring an additional 15,500 shares during the period. Redmile Group LLC raised its position in shares of Silence Therapeutics by 26.3% in the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after acquiring an additional 500,000 shares during the period. Point72 Asset Management L.P. raised its position in shares of Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock worth $4,356,000 after acquiring an additional 165,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Silence Therapeutics by 50.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company’s stock worth $887,000 after acquiring an additional 43,289 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.